My research investigates immune tolerance and seeks to develop new immune therapies for type 1 diabetes and other autoimmune diseases.

Our recent work has focused on how immune pathways control the function of effector and regulatory T cells (Tregs) in the context of autoimmunity. Our studies investigating Type 17 immune pathways in preclinical models of type 1 diabetes have revealed important roles for IL-17 family receptors in diabetes progression. These are linked to changes in T cell function and altered composition of micro-organisms in the gut, such as bacteria.

We have also recently identified factors that can suppress the function of Tregs in type 1 diabetes models. Further study of these pathways may lead to the development of Tregs that have enhanced suppressive functions that could be used to prevent or treat type 1 diabetes.

Key achievements

2017-2021   JDRF International Career Development Award

2016-2017   Diabetes Australia Millennium Award Type 1 Diabetes

2010-2012   JDRF International Postdoctoral Fellowship

2007-2009   NHMRC CJ Martin Postdoctoral Fellowship

2002-2005   Australian Postgraduate Award, Postgraduate Scholarship; University of New South Wales, Faculty of Medicine Postgraduate Scholarship; Cooperative Research Council for Asthma Postgraduate Scholarship; Garvan Institute of Medical Research Postgraduate Scholarship

Related news

Diabetes Australia grant supports new generation research

May 2023

Diabetes Australia grant supports new generation research

Recent research has shown that Tregs, a particular type of immune cell, control the autoimmune responses that cause type 1 diabetes.